Table 1.
Baseline characteristics of the participants
| Controls (n=65) | pH (n=15) | VPA (n=26) | CBZ (n=24) | |
|---|---|---|---|---|
| Age(yr)a,b | 8.3 (3.8) | 7.1 (3.2) | 7.9 (3.3) | 8.3 (3.6) |
| Sex (m/f) | 39/26 | 7/8 | 17/9 | 11/13 |
| Dosage, mg/kg/day | NA | 5-7 | 35-40 | 20-25 |
| Abnormal EEG | NA | 8 | 12 | 10 |
| Duration of treatment, months | NA | 3 | 3 | 3 |
a;
mean (SD).
b
; one-way ANOVA showed no significant difference between groups. n; number of participants. PH; phenobarbital monotherapy group, VPA; sodium valproate monotherapy group, CBZ; carbamazepine monotherapy group. NA; not available.